SCHEMBL6787516

SCHEMBL6787516

C/C(=C/C(=O)Nc1ccc(F)cc1C(=O)O)c1cnc2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.55
DHODH Q02127 4/20 0.48
MGAM O43451 1/20 0.47
KDR P35968 1/20 0.42
TRPM8 Q7Z2W7 2/20 0.42
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41
BCAT1 P54687 1/20 0.40
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 1/20 0.39
MITF O75030 1/20 0.39
XBP1 P17861 1/20 0.39
PAX8 Q06710 1/20 0.39
KLF5 Q13887 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020296 0.84 TERT (0.77) TERTDHODHKDM4E
SCHEMBL6781782 0.81 RAB9A (0.53) TERTDHODHMGAMALDH1A1MAPT
SCHEMBL6792289 0.79 TERT (0.48) TERTDHODHALDH1A1GAAKDM4E
SCHEMBL4020307 0.78 TERT (0.77) TERTDHODHKDM4E
SCHEMBL6782589 0.78 DHODH (0.58) TERTDHODHALDH1A1GAAKDM4E
SCHEMBL6788013 0.77 TERT (0.62) TERTDHODHALDH1A1MAPT
SCHEMBL6790635 0.76 TERT (0.52) TERTDHODHTRPM8
SCHEMBL4025006 0.76 TERT (0.73) TERTALDH1A1GAAKDM4ELMNA
SCHEMBL6787380 0.75 MEN1 (0.52) TERTDHODHMAPT
SCHEMBL6781276 0.75 TERT (0.49) TERTDHODHRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885DHODH 1011/4885MGAM 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.